CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.29B, above the global median of $1.15B
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.72BCNY1.29B · vs all stocks (USD)
Revenue (TTM)
1.86BCNY275.95M · vs all stocks (USD)
Profit Margin
-3.97%Beta
0.3200xvs all stocks
52-Week Change
-12.50%vs all stocks
Market Capitalization
8.72BCNY1.29B · vs all stocks (USD)
Enterprise Value
8.68BCNY1.29B · vs all stocks (USD)
Forward P/E
17.19xPrice to Sales (TTM)
4.78xPrice to Book (MRQ)
1.74xEnterprise to Revenue
4.66xEnterprise to EBITDA
37.10xGross Margin
27.14%Profit Margin
-3.97%Operating Margin
3.17%Return on Assets (TTM)
-0.87%Return on Equity (TTM)
-1.50%Revenue (TTM)
1.86BCNY275.95M · vs all stocks (USD)
Revenue per Share (TTM)
1.15CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-1.54%Gross Profit (TTM)
369.65MCNY54.82M · vs all stocks (USD)
EBITDA (TTM)
404.45MCNY59.98M · vs all stocks (USD)
Net Income (TTM)
-73.86MCNY-10.95M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
186.50%Operating Cash Flow (TTM)
-87.77MCNY-13.02M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
73.64MCNY10.92M · vs all stocks (USD)
5-Year Average Dividend Yield
1.27%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-8.81MCNYFY2025 · Dec 31, 2025Revenue
1.86BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.41BCNYFY2025 · Dec 31, 2025Gross Profit
454.76MCNYFY2025 · Dec 31, 2025Operating Income
-11.28MCNY-1.67M · vs all stocks (USD)
Pre-tax Income
-84.09MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.66MCNYFY2025 · Dec 31, 2025Net Income
-93.75MCNYFY2025 · Dec 31, 2025EBIT
-56.84MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
404.45MCNYFY2025 · Dec 31, 2025Research & Development
116.93MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
98.67MCNYFY2025 · Dec 31, 2025Other Operating Expenses
42.61MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
50.78MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
27.25MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.52BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.52BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-93.75MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.68MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-385.90MCNYFY2025 · Dec 31, 2025Free Cash Flow
-451.11MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.26BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-93.75MCNYFY2025 · Dec 31, 2025Other Non-cash Items
54.95MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-163.71MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-183.39MCNYFY2025 · Dec 31, 2025Capital Expenditures
-65.21MCNYFY2025 · Dec 31, 2025Purchase of Investments
-51.24MCNYFY2025 · Dec 31, 2025Sale of Investments
46.80MCNYFY2025 · Dec 31, 2025Other Investing Activity
377.28MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
307.63MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.45BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.39BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-26.29MCNYFY2025 · Dec 31, 2025Other Financing Charges
67.83MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
103.02MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.62BSharesUpdated Aug 19, 2026Float Shares
892.35MSharesUpdated Aug 19, 2026% Held by Insiders
46.38%vs all stocks
% Held by Institutions
3.06%vs all stocks
Total Cash (MRQ)
858.32MCNY127.29M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5490CNYUpdated Aug 19, 2026Total Debt (MRQ)
1.10BCNY162.59M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2223xCurrent Ratio (MRQ)
1.20xBook Value per Share (MRQ)
3.16CNYUpdated Aug 19, 2026Total Assets
7.33BCNY1.09B · vs all stocks (USD)
Total Current Assets
2.83BCNYFY2025 · Dec 31, 2025Total Liabilities
2.30BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.50BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
86.53MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.22BCNYFY2025 · Dec 31, 2025Cash
1.25BCNYFY2025 · Dec 31, 2025Cash Equivalents
126.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.38BCNYFY2025 · Dec 31, 2025Other Short-term Investments
14.38MCNYFY2025 · Dec 31, 2025Accounts Receivable
424.59MCNYFY2025 · Dec 31, 2025Inventory
901.91MCNYFY2025 · Dec 31, 2025Accounts Payable
783.71MCNYFY2025 · Dec 31, 2025Short-term Debt
1.29BCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.81MCNYFY2025 · Dec 31, 2025Long-term Debt
551.63KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.33MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.62BCNYFY2025 · Dec 31, 2025Retained Earnings
403.43MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.03BCNY746.07M · vs all stocks (USD)
Treasury Stock
177.51MCNYFY2025 · Dec 31, 202552-Week Low
4.87CNYUpdated Aug 19, 202652-Week High
9.09CNYUpdated Aug 19, 202652-Week Change
-12.50%vs all stocks
Beta
0.3200xvs all stocks
50-Day MA
5.29CNYUpdated Aug 19, 2026200-Day MA
6.31CNYUpdated Aug 19, 2026Avg 10-Day Volume
13.74MSharesUpdated Aug 19, 2026Avg 30-Day Volume
18.85MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.0500CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -2.14
Altman Z-Score 2.68: safe zoneNotable
Altman Z-Score: 2.68
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.29B, above the global median of $1.15BNotable
Market cap (USD): 1,293,898,994.088Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ardelyx Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking